Verve Therapeutics (VERV) Competitors $5.24 -0.04 (-0.76%) As of 10:21 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VERV vs. ARQT, TARS, HRMY, TVTX, JANX, IRON, AGIO, APGE, MESO, and VERAShould you be buying Verve Therapeutics stock or one of its competitors? The main competitors of Verve Therapeutics include Arcutis Biotherapeutics (ARQT), Tarsus Pharmaceuticals (TARS), Harmony Biosciences (HRMY), Travere Therapeutics (TVTX), Janux Therapeutics (JANX), Disc Medicine (IRON), Agios Pharmaceuticals (AGIO), Apogee Therapeutics (APGE), Mesoblast (MESO), and Vera Therapeutics (VERA). These companies are all part of the "pharmaceutical products" industry. Verve Therapeutics vs. Arcutis Biotherapeutics Tarsus Pharmaceuticals Harmony Biosciences Travere Therapeutics Janux Therapeutics Disc Medicine Agios Pharmaceuticals Apogee Therapeutics Mesoblast Vera Therapeutics Verve Therapeutics (NASDAQ:VERV) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, community ranking, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability. Which has preferable earnings & valuation, VERV or ARQT? Verve Therapeutics has higher earnings, but lower revenue than Arcutis Biotherapeutics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Verve Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVerve Therapeutics$32.33M14.39-$200.07M-$2.35-2.23Arcutis Biotherapeutics$196.54M9.56-$262.14M-$1.16-13.66 Do insiders & institutionals have more ownership in VERV or ARQT? 97.1% of Verve Therapeutics shares are held by institutional investors. 19.3% of Verve Therapeutics shares are held by insiders. Comparatively, 9.5% of Arcutis Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the MarketBeat Community believe in VERV or ARQT? Arcutis Biotherapeutics received 39 more outperform votes than Verve Therapeutics when rated by MarketBeat users. Likewise, 66.67% of users gave Arcutis Biotherapeutics an outperform vote while only 58.00% of users gave Verve Therapeutics an outperform vote. CompanyUnderperformOutperformVerve TherapeuticsOutperform Votes2958.00% Underperform Votes2142.00% Arcutis BiotherapeuticsOutperform Votes6866.67% Underperform Votes3433.33% Does the media favor VERV or ARQT? In the previous week, Verve Therapeutics had 2 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 12 mentions for Verve Therapeutics and 10 mentions for Arcutis Biotherapeutics. Arcutis Biotherapeutics' average media sentiment score of 1.13 beat Verve Therapeutics' score of 0.36 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verve Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Arcutis Biotherapeutics 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend VERV or ARQT? Verve Therapeutics presently has a consensus price target of $25.50, indicating a potential upside of 386.64%. Arcutis Biotherapeutics has a consensus price target of $18.80, indicating a potential upside of 18.65%. Given Verve Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Verve Therapeutics is more favorable than Arcutis Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Verve Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Arcutis Biotherapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Which has more risk and volatility, VERV or ARQT? Verve Therapeutics has a beta of 1.77, suggesting that its share price is 77% more volatile than the S&P 500. Comparatively, Arcutis Biotherapeutics has a beta of 1.48, suggesting that its share price is 48% more volatile than the S&P 500. Is VERV or ARQT more profitable? Arcutis Biotherapeutics has a net margin of -140.97% compared to Verve Therapeutics' net margin of -807.65%. Verve Therapeutics' return on equity of -35.23% beat Arcutis Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Verve Therapeutics-807.65% -35.23% -27.65% Arcutis Biotherapeutics -140.97%-119.11%-45.95% SummaryVerve Therapeutics beats Arcutis Biotherapeutics on 12 of the 18 factors compared between the two stocks. Remove Ads Get Verve Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VERV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VERV vs. The Competition Export to ExcelMetricVerve TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$467.51M$6.93B$5.64B$8.00BDividend YieldN/A2.73%4.57%4.01%P/E Ratio-2.147.1923.1618.89Price / Sales14.39223.90384.1492.98Price / CashN/A65.6738.1634.64Price / Book0.726.456.904.30Net Income-$200.07M$141.90M$3.20B$247.06M7 Day Performance-5.59%-3.49%-1.69%-0.62%1 Month Performance-17.22%-5.92%2.68%-4.26%1 Year Performance-60.54%-7.90%10.20%0.61% Verve Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VERVVerve Therapeutics1.8444 of 5 stars$5.24-0.8%$25.50+386.6%-60.0%$467.51M$32.33M-2.14110Analyst ForecastARQTArcutis Biotherapeutics2.5565 of 5 stars$17.29+1.6%$18.80+8.7%+67.8%$2.05B$196.54M-9.66150Short Interest ↓Positive NewsTARSTarsus Pharmaceuticals3.1372 of 5 stars$52.36+4.8%$63.67+21.6%+46.5%$2.01B$182.95M-13.7450Insider TradeHRMYHarmony Biosciences4.4831 of 5 stars$34.24-2.9%$53.33+55.8%-0.5%$1.96B$714.73M16.23200TVTXTravere Therapeutics2.8006 of 5 stars$21.29+3.7%$30.62+43.8%+165.6%$1.89B$233.18M-5.19460News CoveragePositive NewsJANXJanux Therapeutics2.6474 of 5 stars$31.74+6.0%$92.44+191.3%-21.5%$1.88B$10.59M-27.1330Positive NewsIRONDisc Medicine2.9773 of 5 stars$53.70+2.8%$93.80+74.7%-13.3%$1.86BN/A-13.4930Insider TradeAGIOAgios Pharmaceuticals4.3645 of 5 stars$32.31+3.2%$56.57+75.1%+5.9%$1.85B$36.50M2.85390Short Interest ↓Positive NewsAPGEApogee Therapeutics2.4302 of 5 stars$40.84+2.5%$92.17+125.7%-42.4%$1.84BN/A-16.8891Positive NewsMESOMesoblast2.025 of 5 stars$14.39+3.2%$18.00+25.1%+281.1%$1.83B$5.67M0.0080Gap UpVERAVera Therapeutics3.1493 of 5 stars$27.15+0.3%$64.67+138.2%-39.5%$1.73BN/A-10.4040Positive News Remove Ads Related Companies and Tools Related Companies Arcutis Biotherapeutics Competitors Tarsus Pharmaceuticals Competitors Harmony Biosciences Competitors Travere Therapeutics Competitors Janux Therapeutics Competitors Disc Medicine Competitors Agios Pharmaceuticals Competitors Apogee Therapeutics Competitors Mesoblast Competitors Vera Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VERV) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verve Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verve Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
